Precision BioSciences prices $75M underwritten offering of common stock and warrants

PRECISION BIOSCIENCES INC

Offering: 10.8M shares + 1.4M pre-funded warrants at $6.14/$6.139995 per unit; gross proceeds ~$75M.
Net proceeds ~$70M after discounts and expenses, expected close Nov 12, 2025.
Each whole warrant exercises at $7.25/share, 5-year term; 4.99% beneficial ownership cap applies.
Proceeds to fund R&D for ARCUS gene editing pipeline and working capital.
Guggenheim Securities sole book-runner; participation from Aberdeen, Bleichroeder, Driehaus, and others.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.